Thomas E. Malcolm, Ph.D.

Thomas E. Malcolm, Ph.D. provides expert counsel to Ferghana Partners Group (FPG) on Gene Editing, Cell Therapy, and Infectious Disease, advising on clinical and scientific matters related to current and prospective clients. With 25 years of experience in genetic regulation of virally infected human cells and human cancers, gene editing of infectious diseases, chimeric antigen receptor therapeutic development, and extracellular vesicle science, Dr. Malcolm brings comprehensive expertise from the biotechnology sector.

As founder, President, and Chief Scientific and Innovations Officer of Caravan Biologix Inc., Dr. Malcolm leads the development of revolutionary technologies designed to overcome the challenges of treating solid tumor cancers with CAR-T cell therapies and delivering gene editors for hereditary and infectious diseases. He also serves as Co-Founder, COO, and Board Member of Kermode Biotechnologies Inc., where he directs innovative approaches to protecting livestock from viral infections including African Swine Fever Virus and Swine Influenza.

Throughout his career, Dr. Malcolm has demonstrated exceptional fundraising capabilities, successfully raising tens of millions of dollars for biotechnology companies at the pure concept to seed stages. His strategic vision and leadership have been instrumental in advancing several groundbreaking technologies, including CRISPR gene editing of viruses, novel drug delivery systems, and toxoid vaccines.

Dr. Malcolm holds several key advisory positions, including membership on the Scientific Advisory Board of Cila Therapeutics Inc. in Boston, MA, which develops inhaled therapies for Primary Ciliary Dyskinesia (PCD) and late-stage SARS-CoV-2 hydrofluidic lung infections. He serves as a scientific advisor and former CSO for Vancouver-based BioMark Diagnostics Inc., advancing metabolomic diagnostics. Additionally, he is a Director on the US Board of Directors for UK-based Gylden Pharma Inc. and a science advisor for the Hippocrates Opportunities Fund in New York.

In 2012, Dr. Malcolm established Criterion BioScience Research Group, a life sciences advisory group focusing on emergent biotechnologies. His executive experience includes serving as a Senior Biochemist at Siemens Healthcare Diagnostics and holding multiple leadership positions as CEO, COO, and CSO throughout his career. His deep expertise spans CRISPR gene editing for human viral infectious diseases including HIV, HBV, and HSV, chimeric antibody receptor therapeutics, animal viruses, oncology, and translational science.

Dr. Malcolm’s research contributions in virology and cancer have been published in numerous high-impact journals, and he is a co-inventor on multiple patents. He earned his Ph.D. in Biochemistry and Molecular Biology from the University of British Columbia, Vancouver, Canada, and completed his postdoctoral studies at Memorial Sloan Kettering Cancer Center and Mount Sinai School of Medicine in New York.